| Acronym |
Full Name |
Score |
Rating |
Judge me |
Search |
| TPA |
12-O-tetradecanoylphorbol-13-acetate |
590 |
7 |
good
bad
|
 |
| TPA |
tissue plasminogen activator |
290 |
5 |
good
bad
|
|
| TPA |
12-O-tetradecanoylphorbol 13-acetate |
216 |
8 |
good
bad
|
|
| TPA |
tissue-type plasminogen activator |
148 |
11 |
good
bad
|
|
| TPA |
12-O-tetradecanoyl-phorbol-13-acetate |
123 |
9 |
good
bad
|
|
| TPA |
tissue polypeptide antigen |
94 |
5 |
good
bad
|
|
| TPA |
12-O-tetradecanoyl phorbol-13-acetate |
82 |
-1 |
good
bad
|
|
| TPA |
tumor promoter 12-O-tetradecanoylphorbol-13-acetate |
59 |
7 |
good
bad
|
|
| TPA |
phorbol ester 12-O-tetradecanoylphorbol-13-acetate |
47 |
6 |
good
bad
|
|
| TPA |
tetradecanoylphorbol acetate |
38 |
3 |
good
bad
|
|
| TPA |
12-O-tetradecanoyl phorbol 13-acetate |
36 |
6 |
good
bad
|
|
| TPA |
12-0-tetradecanoylphorbol-13-acetate |
35 |
0 |
good
bad
|
|
| TPA |
tetradecanoyl phorbol acetate |
30 |
6 |
good
bad
|
|
| TPA |
Tissue-type PA |
27 |
4 |
good
bad
|
|
| TPA |
12-O-tetradecanoyl-phorbol 13-acetate |
23 |
6 |
good
bad
|
|
| TPA |
type plasminogen activator |
21 |
0 |
good
bad
|
|
| TPA |
tumor promoter 12-O-tetradecanoyl-phorbol-13-acetate |
20 |
4 |
good
bad
|
|
| TPA |
12-0-tetradecanoyl phorbol-13-acetate |
14 |
7 |
good
bad
|
|
| TPA |
12-0-tetradecanoyl-phorbol-13-acetate |
12 |
5 |
good
bad
|
|
| TPA |
Treatment with 12-O-tetradecanoylphorbol-13-acetate |
12 |
3 |
good
bad
|
|
| TPA |
tumor promoter 12-O-tetradecanoylphorbol 13-acetate |
11 |
7 |
good
bad
|
|
| TPA |
tumor promotion by 12-O-tetradecanoylphorbol-13-acetate |
10 |
3 |
good
bad
|
|
| TPA |
treated with 12-O-tetradecanoylphorbol-13-acetate |
9 |
3 |
good
bad
|
|
| TPA |
treatment with 12-O-tetradecanoylphorbol 13-acetate |
8 |
16 |
good
bad
|
|
| TPA |
phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate |
8 |
-1 |
good
bad
|
|
| TPA |
tissue type |
7 |
9 |
good
bad
|
|
| TPA |
Time-resolved phosphorescence anisotropy |
7 |
5 |
good
bad
|
|
| TPA |
tumour promoter 12-O-tetradecanoylphorbol-13-acetate |
7 |
5 |
good
bad
|
|
| TPA |
tissue-type |
6 |
7 |
good
bad
|
|
| TPA |
tissue-plasminogen activator |
6 |
5 |
good
bad
|
|
| TPA |
tumor-promoting phorbol ester 12-O-tetradecanoylphorbol-13-acetate |
6 |
1 |
good
bad
|
|
| TPA |
tetradecanoylphorbol-13-acetate |
6 |
0 |
good
bad
|
|
| TPA |
treatment with 12-O-tetradecanoyl phorbol 13-acetate |
5 |
11 |
good
bad
|
|
| TPA |
12-O-tetradecanoylphorbol-13 acetate |
5 |
11 |
good
bad
|
|
| TPA |
Treatment with 12-o-tetradecanoyl phorbol-13-acetate |
5 |
7 |
good
bad
|
|
| TPA |
topical application of 12-O-tetradecanoylphorbol-13-acetate |
5 |
7 |
good
bad
|
|
| TPA |
12-O-tetradecanoylphorbol acetate |
5 |
6 |
good
bad
|
|
| TPA |
tissue PA |
5 |
5 |
good
bad
|
|
| TPA |
12-O-tetradecanoyl-13-phorbol acetate |
5 |
3 |
good
bad
|
|
| TPA |
effects of 12-O-tetradecanoylphorbol-13-acetate |
5 |
2 |
good
bad
|
|
| TPA |
12-O-tetradecanoyl-13-acetate |
5 |
2 |
good
bad
|
|
| TPA |
tumor promoter 12-O-tetradecanoyl phorbol-13-acetate |
4 |
11 |
good
bad
|
|
| TPA |
treated with 12-O-tetradecanoyl-phorbol-13-acetate |
4 |
6 |
good
bad
|
|
| TPA |
type PA |
4 |
5 |
good
bad
|
|
| TPA |
tetradecanoyl phorbol-13-acetate |
4 |
4 |
good
bad
|
|
| TPA |
12-O-tetra-decanoylphorbol-13-acetate |
4 |
4 |
good
bad
|
|
| TPA |
treated with 12-O-tetradecanoyl phorbol-13-acetate |
4 |
2 |
good
bad
|
|
| TPA |
non-12-O-tetradecanoylphorbol-13-acetate |
4 |
2 |
good
bad
|
|
| TPA |
phorbol ester 12-0-tetradecanoylphorbol-13-acetate |
4 |
0 |
good
bad
|
|
| TPA |
tetradecanoylphorbol 13-acetate |
4 |
-2 |
good
bad
|
|
| TPA |
tumor promoter 12-0-tetradecanoyl-phorbol-13-acetate |
3 |
12 |
good
bad
|
|
| TPA |
tumor promotor 12-O-tetradecanoylphorbol-13-acetate |
3 |
9 |
good
bad
|
|
| TPA |
promoter 12-O-tetradecanoylphorbol-13-acetate |
3 |
8 |
good
bad
|
|
| TPA |
tissue-type plasminogen activators |
3 |
8 |
good
bad
|
|
| TPA |
tumor promoting phorbol ester 12-O-tetradecanoylphorbol-13-acetate |
3 |
8 |
good
bad
|
|
| TPA |
12-O-tetradecanoyl 13-acetate |
3 |
7 |
good
bad
|
|
| TPA |
cells with 12-O-tetradecanoylphorbol-13-acetate |
3 |
6 |
good
bad
|
|
| TPA |
effect of 12-O-tetradecanoylphorbol-13-acetate |
3 |
6 |
good
bad
|
|
| TPA |
tumor promoter 12-0-tetradecanoylphorbol-13-acetate |
3 |
6 |
good
bad
|
|
| TPA |
together with 12-O-tetradecanoylphorbol-13-acetate |
3 |
6 |
good
bad
|
|
| TPA |
13-acetate |
3 |
5 |
good
bad
|
|
| TPA |
12-O-tetra-decanoyl-phorbol-13-acetate |
3 |
5 |
good
bad
|
|
| TPA |
tissue plasminogen activator antigen |
3 |
4 |
good
bad
|
|
| TPA |
tumor promoter 12-O-tetradecanoyl phorbol 13-acetate |
3 |
4 |
good
bad
|
|
| TPA |
tumor promoter |
3 |
4 |
good
bad
|
|
| TPA |
12-O-tetradecanoyl-phorbol-acetate |
3 |
4 |
good
bad
|
|
| TPA |
two-photon absorption |
3 |
2 |
good
bad
|
|
| TPA |
treatment with 12-O-tetradecanoyl-phorbol-13-acetate |
3 |
2 |
good
bad
|
|
| TPA |
12-O-tetradecanoyl-phorbol-13 acetate |
3 |
-1 |
good
bad
|
|
| TPA |
inhibit 12-O-tetradecanoylphorbol-13-acetate |
3 |
-2 |
good
bad
|
|
| TPA |
phorbol esters |
2 |
13 |
good
bad
|
|
| TPA |
total peroxidase activity |
2 |
11 |
good
bad
|
|
| TPA |
tumor promoters 12-O-tetradecanoylphorbol-13-acetate |
2 |
11 |
good
bad
|
|
| TPA |
phorbol ester 12-0-tetradecanoyl-phorbol-13-acetate |
2 |
9 |
good
bad
|
|
| TPA |
tumour promoters 12-O-tetradecanoylphorbol-13-acetate |
2 |
8 |
good
bad
|
|
| TPA |
tetradecanoyl phorbol 13 acetate |
2 |
8 |
good
bad
|
|
| TPA |
[3H]12-O-tetradecanoylphorbol-13-acetate |
2 |
7 |
good
bad
|
|
| TPA |
effects of 12-O-tetradecanoyl phorbol-13-acetate |
2 |
5 |
good
bad
|
|
| TPA |
tissue plasminogen activator activity |
2 |
5 |
good
bad
|
|
| TPA |
12-tetradecanoyl phorbol-13-acetate |
2 |
5 |
good
bad
|
|
| TPA |
tumor promoter tetradecanoyl phorbol acetate |
2 |
4 |
good
bad
|
|
| TPA |
Tetragonolobus purpureus |
2 |
4 |
good
bad
|
|
| TPA |
tumor promoter phorbol ester |
2 |
4 |
good
bad
|
|
| TPA |
tetradecanoyl phorbol 13-acetate |
2 |
4 |
good
bad
|
|
| TPA |
12-O-tetradecanoyl phorbol acetate |
2 |
4 |
good
bad
|
|
| TPA |
12-O-tetradecanoyl phorbol ester |
2 |
4 |
good
bad
|
|
| TPA |
texture profile analysis |
2 |
3 |
good
bad
|
|
| TPA |
O-tetradecanoylphorbol 13-acetate |
2 |
3 |
good
bad
|
|
| TPA |
12-0-tetradecanoyl phorbol 13-acetate |
2 |
3 |
good
bad
|
|
| TPA |
tumor promoter phorbol ester 12-O-tetradecanoylphorbol-13-acetate |
2 |
3 |
good
bad
|
|
| TPA |
inhibit the 12-O-tetradecanoylphorbol-13-acetate |
2 |
3 |
good
bad
|
|
| TPA |
tumour promoter 12-O-tetradecanoyl-phorbol-13-acetate |
2 |
3 |
good
bad
|
|
| TPA |
terephthalic acid |
2 |
2 |
good
bad
|
|
| TPA |
8-tetrachlorodibenzo-p-dioxin (TCDD) and 12-O-tetradecanoylphorbol-13-acetate |
2 |
2 |
good
bad
|
|
| TPA |
tumor promoter phorbol 12-myristate 13-acetate |
2 |
2 |
good
bad
|
|
| TPA |
treated with phorbol acetate |
2 |
1 |
good
bad
|
|
| TPA |
tetradecanoyl-phorbol acetate |
2 |
1 |
good
bad
|
|
| TPA |
12-tetradecanoylphorbol 13-acetate |
2 |
1 |
good
bad
|
|
| TPA |
treated with 12-O-tetradecanoylphorbol 13-acetate |
2 |
1 |
good
bad
|
|
| TPA |
tumor promotion with 12-O-tetradecanoylphorbol-13-acetate |
2 |
0 |
good
bad
|
|
| TPA |
treatments with 12-O-tetradecanoylphorbol-13-acetate |
2 |
0 |
good
bad
|
|
| TPA |
12-tetradecanoate 13-acetate |
2 |
0 |
good
bad
|
|
| TPA |
Treatment of cells with 12-O-tetradecanoylphorbol-13-acetate |
2 |
-1 |
good
bad
|
|
| TPA |
Treatment of P3HR-1 cells with 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
18 |
good
bad
|
|
| TPA |
triphenylamine |
1 |
17 |
good
bad
|
|
| TPA |
tissue polypeptide |
1 |
15 |
good
bad
|
|
| TPA |
transpalatal arch |
1 |
14 |
good
bad
|
|
| TPA |
Tetragonolobus purpureas agglutinin |
1 |
14 |
good
bad
|
|
| TPA |
12-O-teradecanoylphorbol-13-acetate |
1 |
14 |
good
bad
|
|
| TPA |
phorbol ester 12-O-tetradecanoyl-phorbol 13-acetate |
1 |
13 |
good
bad
|
|
| TPA |
effect of 12-O-tetra-decanoylphorbol-13-acetate |
1 |
13 |
good
bad
|
|
| TPA |
12-0-tetradecanoyl-phorbol acetate |
1 |
13 |
good
bad
|
|
| TPA |
tumour promoter 12-O-tetradecanoyl phorbol-13-acetate |
1 |
13 |
good
bad
|
|
| TPA |
2-o-tetradecanoyl-13-acetate |
1 |
12 |
good
bad
|
|
| TPA |
tumor-promoting agent 12-O-tetradecanoyl-phorbol acetate |
1 |
12 |
good
bad
|
|
| TPA |
twice weekly with 12-O-tetradecanoylphorbol-13-acetate |
1 |
12 |
good
bad
|
|
| TPA |
tissue plasminogen activator deficiency |
1 |
12 |
good
bad
|
|
| TPA |
tumour-promoting phorbol ester 12-o-tetradecanoyl phorbol 13-acetate |
1 |
12 |
good
bad
|
|
| TPA |
tumor necrosis factor-alpha (TNF-alpha) or 12-O-tetra-decanoylphorbol-13-acetate |
1 |
11 |
good
bad
|
|
| TPA |
serum-treated cells with 12-O-tetradecanoylphorbol-13-acetate |
1 |
11 |
good
bad
|
|
| TPA |
tissue-type plasminogen activator antigen |
1 |
11 |
good
bad
|
|
| TPA |
treatment with phorbol 12-myristate 13-acetate |
1 |
11 |
good
bad
|
|
| TPA |
tumour promotor 12-O-tetradecanoylphorbol-13-acetate |
1 |
11 |
good
bad
|
|
| TPA |
treated with promoting phorbol ester |
1 |
11 |
good
bad
|
|
| TPA |
treated with phorbol-12-myristate-13-acetate |
1 |
11 |
good
bad
|
|
| TPA |
tetradecanoyl-phorbol-acetate |
1 |
10 |
good
bad
|
|
| TPA |
Treatment with Epo or 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
10 |
good
bad
|
|
| TPA |
two photon absorption |
1 |
10 |
good
bad
|
|
| TPA |
Thyroliberin (TRH)- and 12-O-tetradecanoylphorbol 13-acetate |
1 |
10 |
good
bad
|
|
| TPA |
tumor promoters 12-O-tetradecanoyl phorbol-13-acetate |
1 |
10 |
good
bad
|
|
| TPA |
12-O-tetradecanoly phorbol 13-acetate |
1 |
10 |
good
bad
|
|
| TPA |
3H-12-O-tetradecanoylphorbol-13-acetate |
1 |
10 |
good
bad
|
|
| TPA |
tetradecanoylphorbol myristate acetate |
1 |
10 |
good
bad
|
|
| TPA |
ability of 12-O-tetradecanoyl phorbol-13-acetate |
1 |
10 |
good
bad
|
|
| TPA |
Tg and 12-O-tetradecanoylphorbol-13-acetate |
1 |
10 |
good
bad
|
|
| TPA |
topical applications of 2 micrograms 12-O-tetradecanoylphorbol-13-acetate |
1 |
10 |
good
bad
|
|
| TPA |
T-lymphoid leukaemias by 12-o-tetradecanoylphrobol-13-acetate |
1 |
10 |
good
bad
|
|
| TPA |
12-tetradecanoylphorbol myristateacetate |
1 |
10 |
good
bad
|
|
| TPA |
phorbol 12-myristate 13-acetate |
1 |
10 |
good
bad
|
|
| TPA |
consensus o-tetradecanoylphorbol 13-acetate |
1 |
10 |
good
bad
|
|
| TPA |
Three potent 12-O-tetradecanoylphorbol-13-acetate |
1 |
10 |
good
bad
|
|
| TPA |
treatment with 10 ng/ml 12-o-tetradecanoyl-phorbol-13-acetate |
1 |
10 |
good
bad
|
|
| TPA |
treatment with n-butyrate plus 12-O-tetradecanoylphorbol-13-acetate |
1 |
10 |
good
bad
|
|
| TPA |
promoting agent phorbol-12-myristate-13-acetate |
1 |
9 |
good
bad
|
|
| TPA |
transformation of human lymphocytes by 12-0-tetradecanoyl-phorbol-13-acetate |
1 |
9 |
good
bad
|
|
| TPA |
tumor promoter 12-0-tetradecanoyl-phorbol-13-acetate (TPA) |
1 |
9 |
good
bad
|
|
| TPA |
tissue polypeptide antigens |
1 |
9 |
good
bad
|
|
| TPA |
photobinding of tiaprofenic and |
1 |
9 |
good
bad
|
|
| TPA |
temporal processing acuity |
1 |
9 |
good
bad
|
|
| TPA |
tumor promoter 12-O-tetra-decanoylphorbol-13-acetate |
1 |
9 |
good
bad
|
|
| TPA |
treated successively with 12-O-tetradecanoylphorbol-13-acetate |
1 |
9 |
good
bad
|
|
| TPA |
T-lymphocyte mitogen |
1 |
9 |
good
bad
|
|
| TPA |
macrophage activator 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
9 |
good
bad
|
|
| TPA |
tetradecanoate acetate |
1 |
9 |
good
bad
|
|
| TPA |
test the hypothesis that the 12-O-tetradecanoylphorbol-13-acetate |
1 |
9 |
good
bad
|
|
| TPA |
12-O-tetradecanoyl |
1 |
9 |
good
bad
|
|
| TPA |
12-o-tetradecanoyl 13-phorbol acetate |
1 |
9 |
good
bad
|
|
| TPA |
their effect on several 12-O-tetradecanoylphorbol-13-acetate |
1 |
9 |
good
bad
|
|
| TPA |
differentiate by 12-O-tetradecanoylphorbol-13-acetate |
1 |
9 |
good
bad
|
|
| TPA |
complete chemical promoter |
1 |
9 |
good
bad
|
|
| TPA |
those observed with 12-O-tetradecanoylphorbol 13-acetate |
1 |
9 |
good
bad
|
|
| TPA |
12-O-tetradencanoylphorbol-13-acetate |
1 |
9 |
good
bad
|
|
| TPA |
treated with either 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
9 |
good
bad
|
|
| TPA |
either 12-O-tetradecanoylphorbol-13-acetate |
1 |
9 |
good
bad
|
|
| TPA |
Treatment of the cells with 12-O-tetradecanoylphorbol-13-acetate |
1 |
8 |
good
bad
|
|
| TPA |
non-toxic levels of either 12-O-tetradecanoylphorbol-13-acetate |
1 |
8 |
good
bad
|
|
| TPA |
tumor promoters such as phorbol esters |
1 |
8 |
good
bad
|
|
| TPA |
tissue plasminogen activator inhibitor |
1 |
8 |
good
bad
|
|
| TPA |
PKC activator 12-O-tetradecanoylphorbol 13-acetate |
1 |
8 |
good
bad
|
|
| TPA |
O-tetradecanoylphorbol-13-acetate |
1 |
8 |
good
bad
|
|
| TPA |
tumor promoters (like 12-0-tetradecanoylphorbol-13-acetate |
1 |
8 |
good
bad
|
|
| TPA |
12-tetradecanoylphorbol-13-acetate |
1 |
8 |
good
bad
|
|
| TPA |
study 12-O-tetradecanoylphorbol-13-acetate |
1 |
8 |
good
bad
|
|
| TPA |
tumor development was dependent upon 12-O-tetradecanoylphorbol-13-acetate |
1 |
8 |
good
bad
|
|
| TPA |
SENCAR mice on 12-O-tetradecanoylphorbol-13-acetate |
1 |
8 |
good
bad
|
|
| TPA |
r-tissue plasminogen activator |
1 |
8 |
good
bad
|
|
| TPA |
12-O-decanoylphorbol-13-acetate |
1 |
8 |
good
bad
|
|
| TPA |
tumor promoters like 12-O-tetradecanoyl-phorbol-acetate |
1 |
8 |
good
bad
|
|
| TPA |
treatment with 12-o-tetradecanoylphorbor-13-acetate |
1 |
8 |
good
bad
|
|
| TPA |
treatment with cytokines or 12-O-tetradecanoylphorbol-13-acetate |
1 |
8 |
good
bad
|
|
| TPA |
thrombin and 12-O-tetradecanoylphorbol-13-acetate |
1 |
8 |
good
bad
|
|
| TPA |
tissue polypeptide antigeny |
1 |
8 |
good
bad
|
|
| TPA |
tetrapropylammonium |
1 |
8 |
good
bad
|
|
| TPA |
hydroperoxo-copper(II) complex with |
1 |
8 |
good
bad
|
|
| TPA |
differentiate with phorbol ester |
1 |
8 |
good
bad
|
|
| TPA |
tumour promotor 12-O-tetradecanoylphorbol 13-acetate |
1 |
8 |
good
bad
|
|
| TPA |
tumor growth in 100 ng/ml 12-O-tetradecanoylphorbol-13-acetate |
1 |
8 |
good
bad
|
|
| TPA |
treated with acetone or 12-O-tetradecanoylphorbol 13-acetate |
1 |
8 |
good
bad
|
|
| TPA |
these pre-T-ALL cells with 12-0-tetradecanoylphorbol-13-acetate |
1 |
8 |
good
bad
|
|
| TPA |
tissue |
1 |
7 |
good
bad
|
|
| TPA |
TCDD and by 12-O-tetradecanoyl phorbol-13-acetate |
1 |
7 |
good
bad
|
|
| TPA |
tumor associated peptide "Tissue Polypeptide Antigen |
1 |
7 |
good
bad
|
|
| TPA |
tumour-promoting phorbol ester 12-O-tetradecanoyl phorbol acetate |
1 |
7 |
good
bad
|
|
| TPA |
produce it by 12-O-tetradecanoylphorbol-13-acetate |
1 |
7 |
good
bad
|
|
| TPA |
tumor promoter 12 O-tetradecanoylphorbol-13-acetate |
1 |
7 |
good
bad
|
|
| TPA |
10(-7) M 12-O-tetradecanoylphorbol 13-acetate |
1 |
7 |
good
bad
|
|
| TPA |
12-0-tetradecanoyl phorbol-13 acetate |
1 |
7 |
good
bad
|
|
| TPA |
through phorbol ester |
1 |
7 |
good
bad
|
|
| TPA |
tissue-type plasminogen-activator |
1 |
7 |
good
bad
|
|
| TPA |
those induced by 12-O-tetradecanoylphorbol-13 acetate |
1 |
7 |
good
bad
|
|
| TPA |
those caused by treatment with 12-O-tetradecanoylphorbol-13-acetate |
1 |
7 |
good
bad
|
|
| TPA |
suppress 12-O-tetradecanoylphorbol-13-acetate |
1 |
7 |
good
bad
|
|
| TPA |
12-o-tetradecanoyl phorbol 13 acetate |
1 |
7 |
good
bad
|
|
| TPA |
tested inflammatory reactions including 12-O-tetradecanoylphorbol-13-acetate |
1 |
7 |
good
bad
|
|
| TPA |
substitution of Pro-->Ala |
1 |
7 |
good
bad
|
|
| TPA |
Treatment of cells with 12-O-tetradecanoyl phorbol-13-acetate |
1 |
7 |
good
bad
|
|
| TPA |
12-O-tetra decanoyl phorbol-13-acetate |
1 |
7 |
good
bad
|
|
| TPA |
phorbol ester 12-O-tetradecanolyphorbol-13-acetate |
1 |
7 |
good
bad
|
|
| TPA |
two phorbol 12-O-tetradecanoate 13-acetate |
1 |
7 |
good
bad
|
|
| TPA |
an active phorbol ester |
1 |
7 |
good
bad
|
|
| TPA |
tumor-promoting action of 12-O-tetradecanoylphorbol-13-acetate |
1 |
7 |
good
bad
|
|
| TPA |
parasites with 12-O-tetradecanoyl phorbol-13-acetate |
1 |
7 |
good
bad
|
|
| TPA |
influence of 12-O-tetradecanoylphorbol 13-acetate |
1 |
7 |
good
bad
|
|
| TPA |
10 nM 12-O-tetradecanoylphorbol-13-acetate |
1 |
7 |
good
bad
|
|
| TPA |
treatment of R6-plPAT cells with 12-O-tetradecanoylphorbol-13-acetate |
1 |
7 |
good
bad
|
|
| TPA |
tumor promotion induced by 12-O-tetradecanoylphorbol-13-acetate |
1 |
7 |
good
bad
|
|
| TPA |
tumor-promoting phorbol esters 12-O-tetradecanoylphorbol 13-acetate |
1 |
7 |
good
bad
|
|
| TPA |
differentiate by 12-O-tetradecanoylphorbol acetate |
1 |
7 |
good
bad
|
|
| TPA |
tetraphorbol ester |
1 |
7 |
good
bad
|
|
| TPA |
tumor-promoting phorbol ester 12-O-tetradecanoyl phorbol-13-acetate |
1 |
7 |
good
bad
|
|
| TPA |
transfected cells with phorbol ester |
1 |
7 |
good
bad
|
|
| TPA |
two divergent phorbol ester "12-O-tetradecanoylphorbol 13-acetate |
1 |
7 |
good
bad
|
|
| TPA |
treatment suppresses 12-O-tetradecanoylphorbol-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
12-O-tetradecanoxylphorbol 13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
treated with 12-0-tetradecanoylphorbol-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
treated with 100 nM 12-O-tetradecanoylphorbol-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
low-calcium-grown cells and 12-tetradecanoylphorbol-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
tissular plasminogen activator |
1 |
6 |
good
bad
|
|
| TPA |
tumor promoter 12-O-tetradecanoyl-phorbol 13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
treatment with 10 nmol/L 12-tetra decanoylphorbol-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
treated either with 1-beta-arabinofuranosylcytosine or 12-O-tetradecanoylphorbol-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
12-O-tetradecanoyl-4 beta-phorbol-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
tetradecanoyl phorbol-acetate |
1 |
6 |
good
bad
|
|
| TPA |
dimethylsulfoxide or 12-o-tetradecanoylphorbol 13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
treatment for 10-12 weeks with 12-O-tetradecanoylphorbol-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
effect of 12-O-tetradecanoylphorbol 13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
treated with a phorbol ester |
1 |
6 |
good
bad
|
|
| TPA |
tumor-promoting phorbol ester 12-0-tetradecanoyl-phorbol-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
croton oil factor A1 |
1 |
6 |
good
bad
|
|
| TPA |
12-O-tetradecamoylpharbol-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
combination of 12-O-tetradecanoylphorbol-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
change by 12-O-tetradecanoylphorbol 13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
cells incubated with 12-tetradecanoyl-phorbol-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
HMBA inhibited 12-O-tetradecanoylphorbol-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
Treatment of U937 cells with 12-O-tetradecanoylphorbol-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
Treatment with 500 nM 12-0-tetradecanoylphorbol-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
12-0-tetradecanoyl-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
them were 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
are characteristic of 12-O-tetradecanoylphorbol-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
tumor promotion by mirex and 12-O-tetradecanoylphorbol-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
12-O-tetradecanolyphorbol 13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
twice weekly applications of 12-O-tetradecanoylphorbol 13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
5 microM 12-O-tetradecanoylphorbol-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
phorbol ester 12-0-tetradecanoyl-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
tumor promoter tetra-decanoylphorbol acetate |
1 |
6 |
good
bad
|
|
| TPA |
Tissue plasminogen (plgn) activator |
1 |
6 |
good
bad
|
|
| TPA |
160 nM 12-O-tetradecanoylphorbol 13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
(12-O-tetradecanoyl-phorbol-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
presence of 12-O-tetradecanoylphorbol-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
transduction pathway |
1 |
6 |
good
bad
|
|
| TPA |
tissue polypeptic antigen |
1 |
6 |
good
bad
|
|
| TPA |
transfected cells with 12-o-tetradecanoylphorbol 13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
pre-treatment with 12-O-tetradecanoylphorbol 13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
phorbol ester |
1 |
6 |
good
bad
|
|
| TPA |
total parathyroidectomy and autotransplantation |
1 |
6 |
good
bad
|
|
| TPA |
tumor promoters 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
tumour-promoting agent tetradecanoyl-phorbol acetate |
1 |
6 |
good
bad
|
|
| TPA |
12-O-tetra-decanoyl |
1 |
6 |
good
bad
|
|
| TPA |
tannic acid-phosphomolybdic acid-Amidoblack |
1 |
6 |
good
bad
|
|
| TPA |
treated by 12-O-tetradecanoylphorbol 13-acetate |
1 |
6 |
good
bad
|
|
| TPA |
Treponema pallidum |
1 |
6 |
good
bad
|
|
| TPA |
tibialis posterior |
1 |
6 |
good
bad
|
|
| TPA |
Tumour promoters such as 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
these cells after treatment with 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
threshold concentrations of 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
treated with penta-0-ethylquercetin or 12-0-tetradecanoylphorbol 13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
tibial plateau angle |
1 |
5 |
good
bad
|
|
| TPA |
thyroid peroxidase activity |
1 |
5 |
good
bad
|
|
| TPA |
addition of 12-O-tetradecanoylphorbol-13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
treatment of cells with 12-O-tetradecanoyl-phorbol 13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
13-dibutyrate |
1 |
5 |
good
bad
|
|
| TPA |
by 12-O-tetradecanoylphorbol-13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
thrombin-VR1 |
1 |
5 |
good
bad
|
|
| TPA |
Treatment of sarcolemma with 12-O-tetradecanoylphorbol 13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
tumour-promoting phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
addition of 12-0-tetradecanoyl phorbol-13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
presence of 10-O-tetradecanoyl-phorbol-13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
T-cell lines with 12-O-tetradecanoylphorbol-13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
translation factors during 12-O-tetradecanoyl-1-phorbol-13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
peak aperture |
1 |
5 |
good
bad
|
|
| TPA |
phorbolester tetradecanoyl phorbolacetate |
1 |
5 |
good
bad
|
|
| TPA |
tumor promoters phorbol ester |
1 |
5 |
good
bad
|
|
| TPA |
specific binding of [3H]12-O-tetradecanoylphorbol-13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
phorbol diester 12-0-tetradecanoyl-13-phorbolacetate |
1 |
5 |
good
bad
|
|
| TPA |
phorbol ester (12-O-tetradecanoylphorbol-13-acetate) |
1 |
5 |
good
bad
|
|
| TPA |
treatment with 12-0-tetradecanoylphorbol-13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
phorbol ester 12-0-tetradecanoyl-phorbol 13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
phorbolester 12-0-tetradecanoylphorbol 13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
topical applications of 17 nmol 12-O-tetradecanoylphorbol-13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
promoter 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
10(-7) M 12-0-tetradecanoyl-phorbol 13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
trans-acting factors mediating 12-O-tetradecanoylphorbol-13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
tumor promoters viz 12-0-tetradecanoylphorbol-13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
monocytoid lineage by 12-O-tetradecanoylphorbol-13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
tumor polypeptide antigen |
1 |
5 |
good
bad
|
|
| TPA |
Tetradecanoylphorbol-13 acetate |
1 |
5 |
good
bad
|
|
| TPA |
12-0-tetradecanoylphorbol-13- acetate |
1 |
5 |
good
bad
|
|
| TPA |
1-O-tetradecanoylphorbol-13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
tumor promotor 12-O-tetradecanoylphorbol-13 acetate |
1 |
5 |
good
bad
|
|
| TPA |
1 microM 12-O-tetradecanoylphorbol-13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
tumor promoter 12-0-tetradecanoyl phorbol-13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
tetradecanoyl phorbol myristyl acetate |
1 |
5 |
good
bad
|
|
| TPA |
tumor promotion elicited by 12-O-tetradecanoylphorbol-13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
mediate-12-O-tetradecanoyl phorbol 13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
their effects on 12-O-tedtradecanoylphorbol-13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
12-O-tetra-decanoyl phorbol-13-acetate |
1 |
5 |
good
bad
|
|
| TPA |
trans-syn d |
1 |
4 |
good
bad
|
|
| TPA |
transformation of 12-O-tetradecanoylphorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
tumour promoting phorbol ester 12-O-tetradecanoylphorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
Treatment of cells with 12-O-tetradecanoylphorbol 13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
treated with 12-O-tetradecanoylphorobol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
treatment of these cells with 12-O-tetradecanoylphorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
total peptic activity |
1 |
4 |
good
bad
|
|
| TPA |
12-O-tetra-decanoyl-phorbol 13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
Total physical activity |
1 |
4 |
good
bad
|
|
| TPA |
topical application of tetradecanoylphorbol acetate |
1 |
4 |
good
bad
|
|
| TPA |
Treatment with 12-O-tetradecanoyl-phorbol 13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
transformed in vitro after 12-O-tetra-decanoylphorbol 13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
12-tetradecanoyl-13-acetyl-beta-phorbol |
1 |
4 |
good
bad
|
|
| TPA |
lytic replication with 12-O-tetradecanoylphorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
12-O-tetradecanoylphorbol beta-acetate |
1 |
4 |
good
bad
|
|
| TPA |
tumor promoters we used 12-tetradecanoyl-phorbole-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
tumor promoters such as 12-O-tetradecanoyl phorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
12-O-tetradecanoylphorbol-12-acetate |
1 |
4 |
good
bad
|
|
| TPA |
phorbol ester 12-O-tetradecanoyl phorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
12-O-tetradecanoylphorbol 4-acetate |
1 |
4 |
good
bad
|
|
| TPA |
phorbol esters 12-O-tetradecanoylphorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
prepared from 12-O-tetradecanoylphobol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
presence of 12-0-tetradecanyl-phorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
presence of 12-O-tetradecanoylphorbol13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
keratinocytes with 12-O-tetradecanoylphorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
12-O-tetradecanoylphorol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
tumor promotor 12-0-tetradecanoylphorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
12-Q-tetradecanoylphorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
ability of 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
twice weekly applications of 12-O-tetradecanoyl phorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
application of 12-O-tetradecanoyl phorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
be a non-(12-O-tetradecanoylphorbol-13-acetate) |
1 |
4 |
good
bad
|
|
| TPA |
culture with 12-O-tetradecanoylphorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
tumor-promoting phorbol esters |
1 |
4 |
good
bad
|
|
| TPA |
tumor-promoting phorbol ester 12-O-tetra-decanoyl-phorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
inflammation with 12-o-tetradecanoylphorbol acetate |
1 |
4 |
good
bad
|
|
| TPA |
effects of 12-tetradecanoylphorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
inducing agent 12-o-tetradecanoylphorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
process of 12-O-tetradecanoylphorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
tetradecanoylphorbol 12-myristate 13 acetate |
1 |
4 |
good
bad
|
|
| TPA |
treatment with phorbol ester |
1 |
4 |
good
bad
|
|
| TPA |
12-0-tetra-decanoylphorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
tetra-decanoyl phorbol acetate |
1 |
4 |
good
bad
|
|
| TPA |
12-0-tetradecanayl phorbol acetate |
1 |
4 |
good
bad
|
|
| TPA |
treatments of 2 micrograms 12-O-tetradecanoylphorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
Treponema pallidum antibody |
1 |
4 |
good
bad
|
|
| TPA |
12-O-tetradecanoylphorbol- 13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
TGF-beta1 and 12-O-tetradecanoyl phorbol 13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
they were exposed continuously to 12-O-tetradecanoylphorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
Thirty-five patients receiving tissue plasminogen activator |
1 |
4 |
good
bad
|
|
| TPA |
those of 12-O-tetradecanoylphorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
TSH and 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
tenecteplase (TNK) and alteplase |
1 |
4 |
good
bad
|
|
| TPA |
tumor promoter, 12-O-tetradecanoylphorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
screening of 12-0-tetradecanoylphorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
separated 12-O-tetradecanoylphorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
tumor promoter phorbol myristate acetate |
1 |
4 |
good
bad
|
|
| TPA |
tissue polipeptyde antigen |
1 |
4 |
good
bad
|
|
| TPA |
tissue plasminogen |
1 |
4 |
good
bad
|
|
| TPA |
subsequent schedules of 12-O-tetradecanoylphorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
tumor promoter 12-O-tetradecanoylphorbol-13- acetate |
1 |
4 |
good
bad
|
|
| TPA |
T cells with 12-0-tetradecanoyl-phorbol-13-acetate |
1 |
4 |
good
bad
|
|
| TPA |
Tumour-promoting phorbol esters such as 12-O-tetradecanoylphorbol-13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
two stage promotion using 12-O-tetradecanoylphorbol-13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
Two powerful promoters--12-O-tetradecanoylphorbol-13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
two PKC agonists 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
tumour promoter 12-O-tetradecanoyl phorbol 13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
tumor-promoting phorbol esters phorbol tetradecanoate acetate |
1 |
3 |
good
bad
|
|
| TPA |
10(-8) M 12-O-tetradecanoyl-13-phorbol-acetate |
1 |
3 |
good
bad
|
|
| TPA |
tumor promoter phorbol 12-O-tetradecanoate 13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
Tumor promoters like 12-O-tetradecanoylphorbol-13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
100 ng/ml 12-O-tetradecanoylphorbol 13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
tumor promotion caused by 12-O-tetradecanoylphorbol-13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
12-0-tetradodecanoil phorbol 13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
type-plasminogen activator |
1 |
3 |
good
bad
|
|
| TPA |
tumor promoters |
1 |
3 |
good
bad
|
|
| TPA |
tumor promotor 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
tumor-promoting phorbol ester |
1 |
3 |
good
bad
|
|
| TPA |
12-o-tetradecanoyl-phorbol 13 acetate |
1 |
3 |
good
bad
|
|
| TPA |
macrophage lineage with 12-O-tetradecanoylphorbol-13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
interfere with 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
inhibit 12-O-tetradecanoyl phorbol 13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
observed with 12-O-tetradecanoylphorbol-13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
THP-1 stimulated with 12-O-tetradecanoylphorbol 13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
beta-12-O-tetradecanoylphorbol-13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
anti-tissue plasminogen activator |
1 |
3 |
good
bad
|
|
| TPA |
confer 12-O-tetradecanoylphorbol-13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
tessutale |
1 |
3 |
good
bad
|
|
| TPA |
tissue-polypeptide antigen |
1 |
3 |
good
bad
|
|
| TPA |
tissue plasminogen activators |
1 |
3 |
good
bad
|
|
| TPA |
12-O-tetradecanoyl phorbol -13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
times/wk) of 12-O-tetradecanoylphorbol 13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
tetra decanoylphorbol-13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
TNF-alpha- or 12-O-tetradecanoylphorbol-13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
short-term 12-O-tetradecanoyl phorbol 13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
total parenteral alimentation |
1 |
3 |
good
bad
|
|
| TPA |
phorbol ester 12-0-tetradecanoylphorbol |
1 |
3 |
good
bad
|
|
| TPA |
treated with the strongly tumor-promoting 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
all-trans retinoic acid and phorbol ester |
1 |
3 |
good
bad
|
|
| TPA |
tetradecanoyl phorbol myristate acetate |
1 |
3 |
good
bad
|
|
| TPA |
those of 12-0-tetradecanoyl phorbol-13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
tumor-producing phorbol esters |
1 |
3 |
good
bad
|
|
| TPA |
thymocytes to stimulation by 12-O-tetradecanoylphorbol-13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
same when 12-0-tetradecanoylphorbol-13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
2-O-tetradecanoylphorbol 13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
mutagenic potentials of 12-O-tetradecanoylphorbol-13-acetate |
1 |
3 |
good
bad
|
|
| TPA |
nM-tetradecanoylphorbol acetate |
1 |
3 |
good
bad
|
|
| TPA |
12-O-tetradecanylphorbol-13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
early effects of phorbol-12-myristate-13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
tetradecanoyl-13-phorbol acetate |
1 |
2 |
good
bad
|
|
| TPA |
either 12-0-tetradecanoylphorbol-13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
effects of 12-O-tetradecanoyl-13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
12-O-tetradecanoylphorbol-1 3-acetate |
1 |
2 |
good
bad
|
|
| TPA |
phorbol diester |
1 |
2 |
good
bad
|
|
| TPA |
tumor promoting activity of 12-O-tetradecanoyl phorbol-13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
tumor promoting agent 12-0-tetradecanoyl-phorbol-13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
tumor promoting phorbol ester 12-0-tetradecanoylphorbol-13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
tumor promoter-12-O-tetradecanoylphorbol-13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
monocytic pathway by 12-O-tetradecanoylphorbol-13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
non-(12-O-tetradecanoylphorbol-13-acetate) |
1 |
2 |
good
bad
|
|
| TPA |
hepatocytes to 12-O-tetradecanoylphorbol-13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
T cell clone by phorbol-12-myristate-13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
tumor promoter 12-tetradecanoylphorbol-13-myristate |
1 |
2 |
good
bad
|
|
| TPA |
12-0-tetradecanyl phorbol 13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
tissue-type plasminogen |
1 |
2 |
good
bad
|
|
| TPA |
treated with phorbol myristate |
1 |
2 |
good
bad
|
|
| TPA |
treated with either phorbol esters |
1 |
2 |
good
bad
|
|
| TPA |
12-o-tetra-decanoylphorbol 13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
(B[a]P)-initiated/12-O-tetradecanoylphorbol-13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
ability of 12-O-tetradecanoylphorbol-13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
twice-weekly 12-O-tetradecanoyl phorbol-13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
true para-anastomotic aneurysms |
1 |
2 |
good
bad
|
|
| TPA |
Treatment of transformed CEF with 12-tetradecanoylphorbol-13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
Two putative 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
(CEA)-tissue polypeptide antigen |
1 |
2 |
good
bad
|
|
| TPA |
12-tetradecanoyl phorbol 13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
0-tetradecanoylphorbol-13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
tumour promoter 12-tetradecanoyl-phorbol-13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
types when five 12-O-tetradecanoylphorbol-13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
biological action of 12-O-tetradecanoylphorbol-13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
thought that the 12-O-tetradecanoylphorbol-13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
tumour promoting phorbol ester 12-O-tetradecanoylphorbol 13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
asparagus-pea |
1 |
2 |
good
bad
|
|
| TPA |
tumour promotor tetradecanoylphorbol acetate |
1 |
2 |
good
bad
|
|
| TPA |
thyrotropin-releasing hormone (TRH) and 12-O-tetradecanoylphorbol 13-acetate |
1 |
2 |
good
bad
|
|
| TPA |
treatment with 12-O-tetradecanoyl-phorbol-13 acetate |
1 |
1 |
good
bad
|
|
| TPA |
type plasminogen activity |
1 |
1 |
good
bad
|
|
| TPA |
twice-weekly applications of 12-O-tetradecanoylphorbol-13-acetate |
1 |
1 |
good
bad
|
|
| TPA |
D-alpha-tocopherol inhibited 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
1 |
good
bad
|
|
| TPA |
0-tetradecanoyl phorbol-13 acetate |
1 |
1 |
good
bad
|
|
| TPA |
application of 12-O-tetradecanoylphorbol-13-acetate |
1 |
1 |
good
bad
|
|
| TPA |
tumour-promoting agents such as 12-O-tetradecanoyl-phorbol acetate |
1 |
1 |
good
bad
|
|
| TPA |
anti-tisse plasminogen activator |
1 |
1 |
good
bad
|
|
| TPA |
twice weekly 12-O-tetradecanoylphorbol-13-acetate |
1 |
1 |
good
bad
|
|
| TPA |
collagenase 12-O-tetradecanoyl phorbol 13-acetate |
1 |
1 |
good
bad
|
|
| TPA |
mitogen 12-O-tetradecanoylphorbol-13-acetate |
1 |
1 |
good
bad
|
|
| TPA |
typical prepartum activity |
1 |
1 |
good
bad
|
|
| TPA |
12-O-tetradecanoylphorbol-13-O-acetate |
1 |
1 |
good
bad
|
|
| TPA |
suppressing effect of 12-O-tetradecanoylphorbol-13-acetate |
1 |
1 |
good
bad
|
|
| TPA |
10(-8) M 12-O-tetradecanoylphorbol-13-acetate |
1 |
1 |
good
bad
|
|
| TPA |
treatment with a phorbol ester |
1 |
1 |
good
bad
|
|
| TPA |
Thrombin and 12-o-tetradecanoyl-myristyl-13-acetate |
1 |
1 |
good
bad
|
|
| TPA |
tumor promoter 12-O-tetradecanoyl phorbol-13-acetate ester |
1 |
1 |
good
bad
|
|
| TPA |
treatment by 12-O-tetradecanoylphorbol-13-acetate |
1 |
1 |
good
bad
|
|
| TPA |
These genes have the 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
1 |
good
bad
|
|
| TPA |
their anti-inflammatory activity against 12-O-tetradecanoylphorbol-13-acetate |
1 |
1 |
good
bad
|
|
| TPA |
12-O-tetradecanoyl- phorbol 13-acetate |
1 |
1 |
good
bad
|
|
| TPA |
12-O-tetradecanoylphorbal-3-acetate |
1 |
1 |
good
bad
|
|
| TPA |
12-O-tetradecanoyl-phorbol acetate |
1 |
1 |
good
bad
|
|
| TPA |
short-term incubation with 12-O-tetradecanoylphorbol-13-acetate |
1 |
1 |
good
bad
|
|
| TPA |
12-O-tetradecanoylphorbol 13-myristate |
1 |
1 |
good
bad
|
|
| TPA |
plasma cells by 12-O-tetradecanoylphorbol-13-acetate |
1 |
1 |
good
bad
|
|
| TPA |
transformed into macrophage-like cells by 12-0-tetradecanoylphorbol-13-acetate |
1 |
1 |
good
bad
|
|
| TPA |
treated with phorbolesters |
1 |
1 |
good
bad
|
|
| TPA |
topical application of 17 nmol 12-O-tetradecanoylphorbol-13-acetate |
1 |
1 |
good
bad
|
|
| TPA |
collagenase 12-O-tetradecanoyl phorbol-13-acetate |
1 |
0 |
good
bad
|
|
| TPA |
typhimurium (TA 1535/pSK 1002) and 12-O-tetradecanoylphorbol-13-acetate |
1 |
0 |
good
bad
|
|
| TPA |
treated with either insulin or 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
0 |
good
bad
|
|
| TPA |
tissue-specific plasminogen activator |
1 |
0 |
good
bad
|
|
| TPA |
12-O-tertadecanoyl phorbol 13-acetate |
1 |
0 |
good
bad
|
|
| TPA |
TNF or 33 nM 12-O-tetradecanoylphorbol-13-acetate |
1 |
0 |
good
bad
|
|
| TPA |
those of 12-0-tetradecanoylphorbol ester |
1 |
0 |
good
bad
|
|
| TPA |
14-tetramethyl pentadecane (pristane) versus 12-O-tetradecanoylphorbol 13-acetate |
1 |
0 |
good
bad
|
|
| TPA |
Trimethylphenylammonium |
1 |
0 |
good
bad
|
|
| TPA |
be sensitive to 12-O-tetradecanoylphorbol-13-acetate |
1 |
0 |
good
bad
|
|
| TPA |
treated with 12-O-tetradecanoyl-1-phorbol-13-acetate |
1 |
0 |
good
bad
|
|
| TPA |
2-O-tetradecanoylphorbol-13-acetate |
1 |
0 |
good
bad
|
|
| TPA |
3-acetate |
1 |
0 |
good
bad
|
|
| TPA |
12-0-tetradecanoyl-phorbol-13 acetate |
1 |
0 |
good
bad
|
|
| TPA |
curcumin inhibits the 12-O-tetradecanoylphorbol-13-acetate |
1 |
0 |
good
bad
|
|
| TPA |
tetradecanoyl-12-phorbol-13-acetate |
1 |
0 |
good
bad
|
|
| TPA |
12-O-tetradecanoylphorbol 12-acetate |
1 |
0 |
good
bad
|
|
| TPA |
tumor promoting agent 12-O-tetradecanoylphorbol-13-acetate |
1 |
0 |
good
bad
|
|
| TPA |
differentiation-inducer 12-O-tetradecanoylphorbol-13-acetate |
1 |
0 |
good
bad
|
|
| TPA |
tumor-promoting agent phorbol 12-myristate 13-acetate |
1 |
0 |
good
bad
|
|
| TPA |
tumor-promoting phorbol diester 12-O-tetradecanoylphorbol-13-acetate |
1 |
0 |
good
bad
|
|
| TPA |
tetradecanoate phorbol acetate |
1 |
0 |
good
bad
|
|
| TPA |
major 12-O-tetradecanoylphorbol113-acetate |
1 |
0 |
good
bad
|
|
| TPA |
short-term screening method for 12-O-tetradecanoylphorbol 13-acetate |
1 |
0 |
good
bad
|
|
| TPA |
produces tissue-type plasminogen activator |
1 |
0 |
good
bad
|
|
| TPA |
total proteolytic activity |
1 |
-1 |
good
bad
|
|
| TPA |
serum or 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
-1 |
good
bad
|
|
| TPA |
protein kinase C |
1 |
-1 |
good
bad
|
|
| TPA |
entire course of 12-O-tetradecanoylphorbol-13-acetate |
1 |
-1 |
good
bad
|
|
| TPA |
twice weekly applications of 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
-1 |
good
bad
|
|
| TPA |
2 microM of 12-O-tetradecanoylphorbol-13-acetate |
1 |
-1 |
good
bad
|
|
| TPA |
twofold by treatment with tetradecanoylphorbol 13-acetate |
1 |
-1 |
good
bad
|
|
| TPA |
12-tetradecanoyl-phorbol-13-acetate |
1 |
-1 |
good
bad
|
|
| TPA |
4-trimethylquinoline followed by promotion with 12-O-tetradecanoylphorbol-13-acetate |
1 |
-1 |
good
bad
|
|
| TPA |
treating cells with 12-O-tetradecanoyl-phorbol 13-acetate |
1 |
-1 |
good
bad
|
|
| TPA |
treatment of cells with 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
-1 |
good
bad
|
|
| TPA |
o-tetradecanolylphorbol 13-acetate |
1 |
-1 |
good
bad
|
|
| TPA |
block both 12-O-tetradecanoylphorbol-13-acetate |
1 |
-1 |
good
bad
|
|
| TPA |
tumor-promor 12-O-tetradecanoylphorbol-13-acetate |
1 |
-1 |
good
bad
|
|
| TPA |
12-O-tetradecanoylporbol-13-acetate |
1 |
-1 |
good
bad
|
|
| TPA |
TEM followed by promotion with 12-O-tetradecanoylphorbol-13-acetate |
1 |
-1 |
good
bad
|
|
| TPA |
tetradecanoyl phorbol 12-myristate 13-acetate |
1 |
-1 |
good
bad
|
|
| TPA |
12-O-tetradeconylphorbol-13-acetate |
1 |
-1 |
good
bad
|
|
| TPA |
thromboembolism of pulmonary artery |
1 |
-1 |
good
bad
|
|
| TPA |
12-O-tetradecanoyl phorbol13-acetate |
1 |
-1 |
good
bad
|
|
| TPA |
ester-12-O-tetradecanoylyphorbol-13-acetate |
1 |
-1 |
good
bad
|
|
| TPA |
12-O-tetradecanolphorbal-13-acetate |
1 |
-1 |
good
bad
|
|
| TPA |
treatment with 12-O-tetradecanoylphorbol acetate |
1 |
-1 |
good
bad
|
|
| TPA |
12-O-tetradecanoyl-13-phorbol-acetate |
1 |
-1 |
good
bad
|
|
| TPA |
tumors induced following treatment with 12-o-tetradecanoylphorbol-13-acetate |
1 |
-2 |
good
bad
|
|
| TPA |
tumor-promoting dose of 12-O-tetradecanoylphorbol-13-acetate |
1 |
-2 |
good
bad
|
|
| TPA |
treating them with 12-O-tetradecanoylphorbol-13-acetate |
1 |
-2 |
good
bad
|
|
| TPA |
12-0-tetradecanoyl-phorbol-acetate |
1 |
-2 |
good
bad
|
|
| TPA |
phorbol-ester tumor promoter 12-O-tetradecanoylphorbol-13-acetate |
1 |
-2 |
good
bad
|
|
| TPA |
tumor promoting phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate |
1 |
-2 |
good
bad
|
|
| TPA |
tumor promoters such as 12-O-tetradecanoylphorbol 13-acetate |
1 |
-2 |
good
bad
|
|
| TPA |
2-O-tetradecanoyl-phorbol-13-acetate |
1 |
-2 |
good
bad
|
|
| TPA |
alpha-D-glucose phorbol 12-myristate 13-acetate |
1 |
-2 |
good
bad
|
|
| TPA |
ability of 12-O-tetradecanoylphorbol-13 acetate |
1 |
-2 |
good
bad
|
|
| TPA |
Twelve-0-tetradecanoylphorbol-13-acetate |
1 |
-2 |
good
bad
|
|
| TPA |
12-O-tetradecanoylphorbol-beta-acetate |
1 |
-2 |
good
bad
|
|